Protea Biosciences Group Inc

Common Stock SEC Reporting - Current
Verified Company Profile 11/02/2016
Contact Info
  • 1311 Pineview Drive
  • Suite 501
  • Morgantown, WV 26505

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0001335103
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2005
Employees 27 a/o Nov 01, 2016
Company Officers/Contacts
Stephen Turner CEO
David Halverson President
Matthew Powell CSO
Cynthia Price Finance Manager
Company Directors
Stephen Turner Chairman
Steven Antoline
Josiah Austin
Leonard Harris
Stanley Hostler
Roderick Jackson
Ed Roberson
Scott Segal
Service Providers
Accounting/Auditing Firm
Schneider Downs & Co., Inc.
One PP Place
Suite 1700
Suite 1700, PA, 15222
United States
Securities Counsel
1330 Avenue of the Americas
35th Floor
New York, NY, 10019
United States
Investor Relations Firm
ProActive Capital Resources Group, LLC
641 Lexington Ave
Suite 618
New York, NY, 10022
United States
PRGB Security Details
Share Structure
Market Value1 $10,106,710 a/o Mar 24, 2017
Authorized Shares 250,000,000 a/o Mar 22, 2016
Outstanding Shares 149,286,707 a/o Nov 21, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 20,679,540 a/o Mar 22, 2016
Par Value 0.0001
Transfer Agent(s) Verified by Transfer Agent
Island Stock Transfer
Shareholders of Record 519 a/o Mar 22, 2016
Short Selling Data
Short Interest 13,506 (142.04%)
Feb 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security